Medication classes
IL-12/23 inhibitor articles covering treatments such as ustekinumab, including safety, effectiveness, approvals, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
43 articles
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from jnj.com.
Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from msn.com.
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...
A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...
An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...
Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...
A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...
Cure8 found this source from business-standard.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for...
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
